Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P Radermecker

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Revue Medicale De Liege|July 23, 2005
[Risk of hypoglycaemia: therapeutical implications]R P Radermecker
Revue Medicale De Liege|August 20, 2015
[PERSONALIZED MEDICINE AND EBM: ETHICAL ASPECTS]R P Radermecker
Revue Medicale De Liege|July 23, 2005
[Role of insulin secretagogues in the treatment of type 2 diabetes]R P Radermecker
Revue Medicale De Liege|September 12, 2017
[Lipertance® The ASCOT single-pill combination has finally arrived]R P Radermecker
Revue Medicale De Liege|November 19, 2020
[Covid-19 and diabetes]N Paquot, R P Radermecker
Revue Medicale De Liege|August 6, 2010
[How to optimize lipid-lowering therapy: do not forget patient's non-compliance]R P Radermecker, A J Scheen
Revue Medicale De Liege|July 23, 2005
[Insulin therapy in type 1 diabetes]J C Philips, R P Radermecker
Revue Medicale De Liege|July 22, 2004
[Hypoglycaemic coma, a feared paroxysmal phenomenon in type 1 diabetic patient]R P Radermecker, A J Scheen
Revue Medicale De Liege|February 11, 2010
[Ezetimibe (Ezetrol) in patients with diabetes]A J Scheen, R P Radermecker
Revue Medicale De Liege|February 7, 2006
[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes]R P Radermecker, A J Scheen
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Revue Medicale De Liege|July 23, 2005
[Risk of hypoglycaemia: therapeutical implications]R P Radermecker
Revue Medicale De Liege|August 20, 2015
[PERSONALIZED MEDICINE AND EBM: ETHICAL ASPECTS]R P Radermecker
Revue Medicale De Liege|July 23, 2005
[Role of insulin secretagogues in the treatment of type 2 diabetes]R P Radermecker
Revue Medicale De Liege|September 12, 2017
[Lipertance® The ASCOT single-pill combination has finally arrived]R P Radermecker
Revue Medicale De Liege|November 19, 2020
[Covid-19 and diabetes]N Paquot, R P Radermecker
Revue Medicale De Liege|August 6, 2010
[How to optimize lipid-lowering therapy: do not forget patient's non-compliance]R P Radermecker, A J Scheen
Revue Medicale De Liege|July 23, 2005
[Insulin therapy in type 1 diabetes]J C Philips, R P Radermecker
Revue Medicale De Liege|July 22, 2004
[Hypoglycaemic coma, a feared paroxysmal phenomenon in type 1 diabetic patient]R P Radermecker, A J Scheen
Revue Medicale De Liege|February 11, 2010
[Ezetimibe (Ezetrol) in patients with diabetes]A J Scheen, R P Radermecker
Revue Medicale De Liege|February 7, 2006
[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes]R P Radermecker, A J Scheen
Pageof 6